CTOs on the Move

Norwell Visiting Nurse Association and Hospice

www.nvna.org

 
The only independent, free standing, non-profit home health care and hospice agency serving the South Shore, NVNA and Hospice provides care to over 27 communities from Milton to Plymouth. Ten-time winner of the national HomeCare Elite Top Agency award, Top 100 the last two years, NVNA and Hospice offers the full continuum of care from certified and private pay home care, to palliative and hospice care. Non-profit hospice residence, the Pat Roche Hospice Home, offers residential hospice care. Specialty services in Alzheimer`s, Diabetes, CHF, Chronic Disease Self Management, Wound Care, and Falls Prevention. Educational programs, free health screenings, and caregiver ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.nvna.org
  • 120 Longwater Drive
    Norwell, MA USA 02061
  • Phone: 781.659.2342

Executives

Name Title Contact Details
Rachel Langlois
 Chief Information Officer Profile

Similar Companies

Axminster Medical Group

During the past 40 years, AXMINSTER Medical Group has earned the reputation as being a provider of distinctive care and service. The physicians and nurses at AXMINSTER Medical Group believe in a team approach to offering patient care. They work

Bethesda Gardens At Fort Worth

Bethesda Gardens At Fort Worth is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pacific Companies

Pacific Companies is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NexgenRx

NexgenRx is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.